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Abstract
Escherichia coli is a heavily used platform for the production of biotherapeutic and
other high‐value proteins, and a favored strategy is to export the protein of interest
to the periplasm to simplify downstream processing and facilitate disulfide bond
formation. The Sec pathway is the standard means of transporting the target protein
but it is unable to transport complex or rapidly folding proteins because the Sec
system can only transport proteins in an unfolded state. The Tat system also operates
to transport proteins to the periplasm, and it has significant potential as an
alternative means of recombinant protein production because it transports fully
folded proteins. Here, we have tested the Tat system’s full potential for the
production of biotherapeutics for the first time using fed‐batch fermentation. We
expressed human growth hormone (hGH) with a Tat signal peptide in E. coli W3110
“TatExpress” strains that contain elevated levels of the Tat apparatus. This construct
contained four amino acids from TorA at the hGH N‐terminus as well as the initiation
methionine from hGH, which is removed in vivo. We show that the protein is
efficiently exported to the periplasm during extended fed‐batch fermentation, to the
extent that it is by far the most abundant protein in the periplasm. The protein was
shown to be homogeneous, disulfide bonded, and active. The bioassay showed that
the yields of purified periplasmic hGH are 5.4 g/L culture whereas an enzyme‐linked
immunosorbent assay gave a figure of 2.39 g/L. Separate analysis of a TorA signal
peptide linked to hGH construct lacking any additional amino acids likewise showed
efficient export to the periplasm, although yields were approximately two‐fold lower.
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1 | INTRODUCTION
Many high‐value proteins are produced in Escherichia coli, and a
favored strategy is to export the protein to the periplasm, usually by
the well‐characterized “Sec” pathway (Walsh, 2014). Several strate-
gies have been used, including expression of soluble proteins in the
cytoplasm, expression in the form of insoluble inclusion bodies, or
export to the periplasm. The latter approach is particularly favored
for the production of proteins that contain disulfide bonds, because
the periplasm is the only oxidizing compartment in wild‐type (WT)
cells (Pooley, Merchante, & Karamata, 1996). Downstream proces-
sing is also simplified due to the lowered levels of cytoplasmic
contaminants, including DNA (Balasundaram, Harrison, & Bracewell,
2009). Export of proteins to the periplasm is usually achieved by
targeting via the well‐characterized Sec pathway, whereby a
cleavable Sec‐specific signal peptide is present at the N‐terminus of
the target protein. However, the Sec pathway cannot transport some
heterologous proteins and attention has focused on the alternative
Tat pathway, which transports fully folded proteins by a completely
different pathway (reviewed by Natale, Bruser, & Driessen, 2008).
Initial studies showed that Tat could export a model protein, green
fluorescent protein, at high levels and that the cells were robust
under fermentation conditions (Matos et al., 2012). This work was
followed by additional studies that showed Tat to be capable of
exporting several biotherapeutics, including human growth hormone
(hGH), single chain antibody fragments, and interferons (Alanen et al.,
2015; Browning et al., 2017; DeLisa, Tullman, & Georgiou, 2003;
Matos et al., 2014; Tullman‐Ercek et al., 2007).
hGH is a 22 kDa protein consisting of 191 amino acids (Pooley
et al., 1996) used to treat burn injuries, wound healing, hypopituitar-
ism, and obesity (Isaksson, Edén, & Jansson, 1985) because it is safe
to use even in high doses (Van Loon, 1998). Because hGH only has
two disulfide bonds (Cys53–Cys165 and Cys182–Cys189; Ultsch,
Somers, Kossiakoff, & Devos, 1994) and no glycosylation, most of its
large‐scale production has used E. coli platforms, although a wide
range of eukaryotic host systems have been tested (e.g., Ecamilla‐
Trevino, Viader‐Salvado, Barrera‐Saldana, & Guerrero‐Olazaran,
2000; Hahm & Chung, 2001). The highest recorded yield is 5 g of
recombinant hGH per liter of milk in transgenic cows (Salamone
et al., 2006).
A major difficulty in producing hGH in E. coli is its aggregation
into insoluble bodies that complicate the production process. Until
recently, most commercial hGH has been obtained from insoluble
bodies that have been solubilized, with the hGH refolded into its
active form (Olson et al., 1981; Patra et al., 2000). Recent, novel
approaches have managed to produce high quantities of cytosolic
hGH in fed‐batch fermentation, with reported yields of up to 678mg/
L protein (Song, Jiang, Wang, & Zhang, 2017).
Although studies exporting hGH to the periplasm have reported
relatively low yields (Sockolosky & Szoka, 2013), this is an attractive
option due to the ease of downstream processing. In recent studies, we
have shown that the Tat system can export hGH with high efficiency
and that it is disulfide bonded (Alanen et al., 2015). Our study concluded
that although the protein was presumably synthesized and exported in
the reduced state, the periplasmic protein was fully disuphide bonded
by the normal DSB disulfide bonding system. We have also reported
that a new series of engineered E. coli strains, which overexpress the Tat
system components (termed TatExpress), demonstrate even higher
export efficiencies (Browning et al., 2017). These strains bear a modified
chromosomal tatABC operon, the expression of which is induced by
isopropyl‐β‐D‐thiogalactoside (IPTG), so that the Tat system is over-
expressed at the same time as the IPTG‐induced target protein.
However, the activity of the hGH was not assayed and our studies
(Alanen et al., 2015; Browning et al., 2017) used laboratory shake flask
systems that bear little resemblance to industrial production processes.
Here, we have assessed the feasibility of this system for industrial
production using TatExpress E. coli strains under fed‐batch fermentation
conditions. We report that the system is able to produce purified,
disulfide bonded, active hGH at levels that are calculated to be between
2 and 5 g/L culture.
2 | MATERIALS AND METHODS
2.1 | Bacterial strains and plasmids
Strains and plasmids are summarized in Table 1. E. coli strain W3110
was used, together with W3110 TatExpress which was previously
described in Browning et al. (2017) alongside the plasmid pKRK7
(pEXT22 expressing TorA–hGH–6His). pKRK38 was derived from
pKRK7 to eliminate the TorA signal peptide that precedes the hGH.
pKRK38 was made by polymerase chain reaction (PCR) amplification
using pKRK7 as a template and primers Mature_hGH_F (5′‐
ATGTTCCCAACCATTCCCTTATCCA‐3′) and Mature_hGH_R (5′‐
CATACATGTTCCTCTGTGGTAGGGT‐3′) as forward and reverse
primers. PCR solutions, enzymes and reaction conditions were as
described in Guerrero‐Montero et al. (2019).
TABLE 1 Strains and plasmids used in this work
Strains/plasmids Description Source/reference
W3110 E. coli K‐12 strain. F−, λ−, IN(rrnD‐rrnE)1 rph‐1 Hayashi et al. (2006)
W3110 TatExpress W3110 carrying a ptac promoter upstream of tatABCD Browning et al. (2017)
pKRK7 pEXT22 expressing TorA–hGH–6His Browning et al. (2017)
pKRK36 pEXT22 expressing hGH–6His This work
pCJ14 As pKRK36 but lacking four residues of mature TorA and the hGH initiation methionine This work
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An additional TorA–hGH construct was made removing the four
initial amino acids of mature TorA and the N‐terminal methionine of
hGH. The construct was made by Gibson assembly in which the
hGH–His6 was amplified from plasmid pKRK7 (pEXT22, TorA–hGH–
His6) and inserted into a pEXT22 backbone in which the TorA signal
sequence had already been cloned. Colonies were screened colony
PCR and confirmation of the intended deletion was provided by
sequencing from Eurofins Genomics.
Primer name Sequence
hGH_del.FOR AACGCCGCGACGTGCGACTGCGTTCCCA
ACCATTCCCTTATCCAGGC
hGH_del.REV TTAATGGTGATGGTGATGGTGGAAGCCA
CAGCTGCCCTCC
TorA_del.FOR GTGGAGGGCAGCTGTGGCTTCCACCAT-
CACCATCACCATTAATAAGGATCTATAT-
GACTAG
TorA_del.REV ATAAGGGAATGGTTGGGAACGCAGTCGCA
CGTCGCGG
2.2 | Fed‐batch fermentation
Initial cultures were grown in 50ml of 2XP media (16 g/L of Bacto‐
tryptone/peptone, 10 g/L of yeast extract, 10 g/L NaCl) in 250ml
shake flasks for 6 hr at 37°C, 200 rpm with 1:1,000 antibiotic (5 μl,
1M kanamycin). One milliliter of culture was transferred to two
hundred milliliters of SM6 defined media (Humphreys et al., 1998)
and grown aerobically overnight at 30°C, 200 rpm in shake flasks
with 1:1,000 antibiotic (5 μl, 1M kanamycin). On the following day,
an equivalent of 300 OD600 was used to inoculate fresh defined SM6
media to a final volume of 500ml in Infors Multifors 1.5 L fermenters
(Infors UK Ltd., Reigate, UK). The pH was kept at 7 using 25% (vol/
vol) ammonia solution and 25% (vol/vol) sulfuric acid. Dissolved
oxygen tension was kept at 30% using gas blending with 100%
oxygen where necessary, and the culture was maintained at 30°C
until both stirrer and airflow was maximal and then dropped to 25°C.
Supplementation of MgSO4 occurred when the OD600 reached
38–42 (8ml/L of 1M MgSO4) and of Na2HPO4 when the OD600
reached 54–58 (5 ml/L of 232.8 g/L Na2HPO4) and when the OD600
reached 66–77 (7 ml/L of 232.8 g/L Na2HPO4). A glycerol feed
containing 80% wt/wt glycerol was started at OD600 70, with a
continuous feed of 0.01ml/min. Induction with 9ml/L of IPTG at a
concentration of 4.31 g/L occurred at OD600 75.
2.3 | Fractionation
Cytoplasm, membrane, and periplasm fractions were prepared by an
osmotic‐shock method. Cells were centrifuged at 3,000g, 4°C, for
10min and resuspended in 500 µl of Buffer 1 (100mM Tris‐acetate
pH 8.2, 500mM sucrose, 5 mM ethylenediaminetetraacetic acid
[EDTA] pH 8.0) and 500 µl dH2O before addition of 40 µl hen egg
white lysozyme (1mg/ml) and incubation on ice for 5min. Twenty
microliter MgSO4 (1M) was added and the suspension was
centrifuged at 20,000g, 4°C, 2 min. The supernatant containing the
periplasmic fraction was removed and the pellet washed once in
750 µl Buffer 2 (50 mM Tris‐acetate pH 8.2, 250mM sucrose, 10mM
MgSO4). The cell pellet was resuspended in 750 µl Buffer 3 (50mM
Tris‐acetate pH 8.2, 2.5 mM EDTA pH 8.0) and sonicated for 6 × 10 s,
amplitude 8 µm to disrupt membranes (Soniprep 150 Plus, Sanyo
Gallenkamp; Loughborough, UK). The suspension was centrifuged at
202,000g, 4°C, 30min to sediment the insoluble fraction. Five
hundred microliter of the supernatant was removed (designated
cytoplasmic fraction). The remainder of the supernatant was
discarded and the pellet resuspended in 500 μl Buffer 3 and
designated membrane (or insoluble) fraction.
2.4 | Protein purification
For purification of 6X Histidine‐tagged (C‐term) proteins by Nickel
IMAC, 10ml of the culture post‐induction was taken, centrifuged at
3,000 rpm, 45min, 4°C. Cell pellet was resuspended in 10ml/g of
chilled Buffer 1 without EDTA and 10ml/g of milliQ H2O and
incubated on ice for 30min before centrifuging at 20,000g, 20 min,
4°C (Beckman Avanti J‐ 25, JA 25.5 rotor). Supernatant was taken as
the periplasmic fraction and placed into SnakeSkin® dialysis tubing
(Thermo Fisher Scientific) and dialysed at 4°C overnight into 50mM
sodium phosphate, 150mM NaCl, pH 7.2. Using an ÄKTA™ pure
protein purification system and a HisTrap HP histidine‐tagged
protein column (GE Healthcare, Buckinghamshire, UK) the protein
was purified. Storage solution (20% ethanol) was washed off with 10
column volumes (CV) of milliQ H2O before adding 5ml 0.2M NiCl,
followed by another 2 CV milliQ H2O wash. Columns were
equilibrated with 3 CV equilibration buffer (50mM sodium phos-
phate pH 7.2, 0.3M NaCl) before loading Periplasmic sample and
collecting flow through. Unbound matter was removed with 6 CV
wash buffer (50mM sodium phosphate pH 7.2, 50mM imidazole,
0.3M sodium chloride) and sample collected as wash. Finally, the 6X
Histidine‐tagged protein was eluted with elution buffer with
imidazole (50mM sodium phosphate pH 7.2, 0.3M NaCl with
250mM imidazole) and the peaks collected for analysis.
2.5 | Protein expression analysis by Coomassie and
western blot
Protein samples were resolved by reducing sodium dodecyl sulfate‐
polyacrylamide gel electrophoresis (SDS‐PAGE) and analyzed using
Coomassie blue staining and western blotting. All immunoblotting
procedures were as described in Guerrero‐Montero et al. (2019).
Periplasmic hGH activity was assayed using an hGH bioassay
(PathHunter® Human Growth Hormone Bioassay Kit, Sigma) using
the manufacturer’s protocol. Standardized OD10 periplasmic frac-
tions were diluted 1:500,000 using phosphate‐buffered saline and
absorbance was read using a BMG LABTECH SPECTROstar micro-
plate reader at 405 nm, with a reference wavelength at 490 nm.
Concentrations were calculated from two independent experiments
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and all samples were measured in triplicate when calculating
periplasmic yield. Periplasmic hGH was also assayed using an hGH
ELISA kit (Roche Diagnostics, West Sussex, UK) using the manufac-
turer’s protocol. Concentrations were calculated from two indepen-
dent experiments and all samples measured in triplicate, and used to
calculate average periplasmic yield (in mg/L) by reference to culture
OD readings at 600 nm.
2.6 | Intact protein electrospray liquid
chromatography–mass spectrometry (LC‐MS)
The electrospray mass spectrum was recorded on a Bruker
micrOTOF‐Q II mass spectrometer. An aliquot of protein in solution,
corresponding to approximately 20 pmol of protein, was desalted
online by reverse‐phase high performance liquid chromatography
(HPLC) on a Phenomenex Jupiter C4 column (5 µm, 300Ǻ, 2.0 mm ×
50mm) running on an Agilent 1100 HPLC system at a flow rate of
0.2 ml/min using a short water, acetonitrile, 0.05% trifluoroacetic
acid gradient. The eluent was monitored at 280 nm and directed into
the electrospray source, operating in positive ion mode, at 4.5 kV and
mass spectra recorded from 500 to 3,000m/z. Data were analyzed
and deconvoluted to give uncharged protein masses using Bruker’s
Compass Data Analysis software.
3 | RESULTS
3.1 | Fed‐batch fermentation of WT and
TatExpress cells expressing TorA–hGH
We first expressed a construct comprising the TorA signal peptide
linked to hGH (TorA–hGH) in W3110 E. coli TatExpress cells under
fed‐batch fermentation conditions as detailed in Materials and
Methods. The construct was previously used in shake flask studies
(Browning et al., 2017) and comprises the signal peptide of E. coli
TMAO reductase (TorA) linked to hGH via a four‐residue linker (the
first four residues of mature TorA; AQAA). The construct encodes
the initiation methione of hGH (which is removed in vivo) and also
contains a C‐terminal 6‐His tag. Parallel cultures were carried out
with the construct expressed in WT W3110 cells. Figure 1 shows the
growth curves from the cultures; duplicate WT and TatExpress
cultures reached ODs of approximately 100 and Figure 1 shows the
point at which induction of TorA–hGH and TatABC synthesis (in
TatExpress) was induced using IPTG.
Samples were removed 13, 17, and 21 hr after induction and the
cells were fractionated to generate cytoplasmic, membrane and
periplasmic samples. The periplasmic samples were analyzed by
immunoblotting to detect the hGH and the same samples were
analyzed using Coomassie‐stained SDS‐PAGE gels to analyse the
proteome of the periplasmic samples. Figure 2 shows the 13 and
21 hr samples from the twoWT cultures, which indicate the presence
of a clear hGH protein band in the periplasm. The Coomassie‐stained
gel shows the presence of a 22 kDa protein, the relative abundance
of which matches the strength of the blot signals. This was confirmed
to be hGH (see below). Also analyzed were 13, 17, and 21 hr samples
from the two TatExpress cultures, and the data show that the hGH
blot signals are significantly higher than those of the WT cultures,
confirming that TatExpress cells export this construct with much
higher efficiency as observed by Browning et al. (2017) in shake flask
culture. The abundance of the 22 kDa protein is correspondingly
greater in the Coomassie‐stained gels, providing further evidence
that this is indeed hGH.
Figure 3 shows a time course analysis of the abundance of the
periplasmic hGH after induction of synthesis in TatExpress cells.
Samples were taken from 2 to 51 hr after induction and the blot
shows a steady increase in hGH level over this time period. Equal
numbers of cells were used in each sample, so this reflects an
F IGURE 1 Growth data during fed‐batch fermentation of Escherichia coli W3110 WT and TatExpress cells expressing TorA–hGH. Duplicate
cultures were analyzed of WT cells (WT1, WT2) and TatExpress (TE1, TE2), with OD600 nm values shown. Fermentation was carried out at 30°C
as detailed in Materials and Methods. At the indicated times, the cultures were induced with IPTG (0.1 mM) and samples were removed for
analysis. IPTG, isopropyl‐β‐D‐thiogalactoside; TorA–hGH, TorA signal peptide linked to hGH; WT, wild‐type
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increase in the amount of hGH per cell. The Coomassie gel confirms
that the abundant 22 kDa protein is indeed hGH, because its
abundance increases in parallel and the protein is virtually absent
in the induction time point samples. Analysis of the later time points
demonstrates that hGH is by far the most abundant periplasmic
protein, which shows that Tat is exporting high amounts of protein.
We have carried out controls for fractionation artifacts in previous
studies, and the periplasmic proteome is clearly distinct from that of the
cytoplasm, suggesting that contamination of cytoplasmic proteins is
minimal (e.g., Matos et al., 2012). However, to confirm this point we
fractionated samples at the 21 hr time point and the data are shown in
Figure 4. The results show that the fractions are indeed “clean” with the
periplasmic proteome clearly distinct from those of the cytoplasm and
membrane fractions. To further confirm that hGH does not reach the
F IGURE 2 Tat‐dependent export of TorA–hGH in W3110 wild‐
type (WT) and TatExpress W3110 cells. Samples from duplicate fed‐
batch fermentation cultures of WT and TatExpress expressing
TorA–hGH were removed at the indicated times postinduction and
fractionated to yield periplasmic samples. The periplasmic samples
were analyzed by Coomassie blue stained gels (a) and
immunoblotting using antibodies to the His tag on hGH (b). For each
lane a normalized amount of protein has been loaded, equivalent to
OD600 0.08 AU total cells (Coomassie blue stained gels), and OD600
0.008 AU (immunoblots). Mobilites of molecular weight markers (in
kDa) are shown on the left. TorA–hGH, TorA signal peptide linked to
hGH
F IGURE 3 High‐level export of TorA–hGH during extended fed‐
batch fermentation of TatExpress cells. TorA–hGH was expressed in
TatExpress cells in a fed‐batch fermentation system and samples
were removed at the indicated times postinduction (PI). The samples
were fractionated to generate periplasm samples which were then
analyzed on Coomassie blue stained gels (a) and by immunoblotting
using antibodies to the His tag on hGH (b). hGH, human growth
hormone; TorA–hGH, TorA signal peptide linked to hGH
F IGURE 4 Fractionation of samples from fed‐batch fermentation of
W3110 wild‐type (WT) and TatExpress cells expressing TorA–hGH.
Samples from the 21 hr time point of fed‐batch fermentation cultures of
WT and TatExpress (TE) expressing TorA–hGH (shown in Figure 2)
were fractionated to yield cytoplasm, membrane, and periplasm
samples (C, M, and P). The samples were analyzed by Coomassie blue
stained gels (a) and immunoblotting using antibodies to the His tag on
hGH (b). For each lane a normalized amount of protein has been loaded,
equivalent to OD600 0.08AU total cells (Coomassie blue stained gels),
and OD600 0.008AU (immunoblots). Mobilites of molecular weight
markers (in kDa) are shown on the left. TorA–hGH, TorA signal peptide
linked to hGH
F IGURE 5 Mature hGH is not exported during fed‐batch
fermentation of TatExpress. Mature‐size hGH and TorA–hGH were
expressed in TatExpress cells using fed‐batch fermentation systems.
Samples were removed 1 and 18 hr postinduction and fractionated
to generate cytoplasm, membrane, and periplasm samples (C, M, and
P) which were then analyzed by immunoblotting using antibodies to
the His tag on hGH. hGH, human growth hormone; TorA–hGH, TorA
signal peptide linked to hGH
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periplasmic fraction “spontaneously” we expressed hGH lacking any
form of signal peptide. Mature hGH was expressed in parallel with
TorA–hGH and samples were fractionated after 1 and 18 hr induction
(Figure 5). The immunoblot shows that the bulk of hGH is in the
periplasm in the TorA–hGH culture, as expected, with a minimal level of
protein present in the cytoplasm at the 18 hr point. In contrast, hGH is
found exclusively in the cytoplasm in the sample expressing mature
hGH, with none detected in the periplasmic fraction. These data confirm
that the presence of hGH in the periplasm of the TorA–hGH cultures is
due to Tat‐dependent export and not contamination by cytoplasmic
fraction or spontaneous transfer across the plasma membrane.
It is notable that the total level of hGH in the culture producing
mature hGH is approximately sixfold lower than that in the
TorA–hGH culture. This reflects a phenomenon observed previously
in our shake flask studies that hGH is subjected to rapid turnover in
the cytoplasm (Alanen et al., 2015). Clearly, this protein is more
stable in the periplasm, and this is another advantage of using an
effective protein export strategy for the production of this particular
protein.
3.2 | TAT‐exported hGH is homogeneous
and cleaved at the correct signal peptidase site
To assess the homogeneity of the exported hGH, we performed mass
spectrometry analysis of the purified protein, using purified
commercial hGH as a standard (provided with the Pathfinder
Bioassay—see below). The exported, periplasmic hGH construct used
in this study should contain additional amino acids when compared to
commercial hGH, specifically the four amino acid linker from the
mature TorA protein (TMAO reductase) at the N‐terminus, the
initiation methionine (cleaved from hGH in vivo) and the 6‐His tag at
the C‐terminus (Figure 6). The combined molecular weight of the
additional amino acids is 609.7 for the N‐terminal residues and
822.86 for the C‐terminal His tag (1,432.56 in total). The predicted
molecular weights are 22,129.05 for the commercial hGH, and
23,561.5 for the exported hGH. As shown in Figure 6, mass
spectrometry analysis of commercial hGH gives a single prominent
peak corresponding to 22,124.3 Da, which matches almost exactly
with the predicted molecular mass, having only a difference of
4.75 Da, four of which are a consequence of the formation of two
disulfide bonds. We purified the Tat‐exported periplasmic hGH using
affinity chromatography and an analysis of this protein again shows a
single prominent peak, and the mass of 23,555 Da is again very close
to, but 6 Da smaller than the predicted mass of 23,561Da. The
presence of two disulfide bonds again accounts for the difference. In
both cases, the 1–2 Da deviation from the predicted protein masses
is within the error range for the mass spectrometer.
Other smaller peaks are observed in both samples, which appear
to be an artifact of the hGH mass spectrometry because they are
identical in the two samples. This implies that the hGH produced in
this study is (a) as homogeneous as the commercial protein; (b)
processed at the correct site; and (c) fully disulfide bonded; there is
no indication of a peak corresponding to the reduced form.
To confirm that the hGH is indeed disulfide bonded, we ran
samples of the periplasmic samples from the 51 hr time point shown
in Figure 3 on an SDS‐PAGE gel in the presence and absence of
reducing agent. The oxidized, disulfide bonded form of hGH was
shown to migrate more rapidly than the reduced form (Alanen et al.,
2015) and Figure 7 shows the periplasmic hGH from the fed‐batch
fermentation likewise runs more rapidly under oxidizing conditions,
further confirming that the protein is disulfide bonded. It is unclear
why the intensity of the blot signal is lower; presumably, the C‐
terminal His tag is less exposed in the oxidized protein and the
antibodies bind less effectively.
3.3 | High yields of active protein are obtained
from fed‐batch fermentation using TorA–hGH
To quantify the yield of periplasmic hGH and to assess its activity, we
used a commercially available hGH bioassay (PathHunter® Human
Growth Hormone Bioassay Kit, Sigma). This uses engineered cells in
which one fragment of β‐galactosidase is present on the hGH
receptor and the complementary fragment is present on a phosphor‐
tyrosine SH2‐domain‐containing protein that is only able to bind the
hGH receptor once it is activated. Binding of hGH to its receptor
results in receptor phosphorylation by a cytosolic tyrosine kinase
such as JAK1, enabling the SH2‐EA fusion protein to bind the
phosphorylated receptor and generate active β‐galactosidase. Enzy-
matic activity is quantitatively measured using a chemiluminescent
substrate, and the expected result is a dose‐response sigmoidal
function where the phosphorylation of the receptor will be
dependent on the amount of hGH in the sample. A standard curve
was produced with the supplied commercial hGH and all samples
were done in triplicate and with dilution factors in the range of the
standard curve (see Figure S2). This assay gave a figure of 5.4 g hGH
per litre of fed‐batch culture for the purified periplasmic hGH shown
in Figure S1.
We also calculated hGH levels using a commercial enzyme‐linked
immunosorbent assay (ELISA), which uses prebound antibodies to
hGH on the surface of the microplate modules. The sample to analyse
was added in triplicate (with various dilution factors) to the wells, and
the hGH present in the samples binds to the anti‐hGH antibodies.
Afterwards a digoxigenin‐labeled antibody to hGH is added which
binds to the hGH as well. An antibody to digoxigenin conjugated to
peroxidase is added and binds to the digoxigenin, and finally the
peroxidase substrate ABTS is added. The peroxidase catalyzes
the cleavage of the substrate yielding a colored reaction product
that can be measured using a plate reader that reads at 405 and
490 nm. The absorbance is directly correlated to the level of hGH
present in the sample and can be determined by comparison to
the calibration curve (shown in Figure S3). Using this ELISA the
concentration of the purified periplasmic hGH was calculated to be
2.39 g/L culture. This is lower than the figure obtained using the
bioassay, but because the assays are so different it is difficult to
determine which is more accurate.
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3.4 | Export of TorA–hGH lacking the four‐residue
linker between the signal peptide and hGH
The above experiments were all carried out using a construct that
comprises the TorA signal peptide, four residues from the N‐terminus
of mature TorA and hGH. This construct was used to compare results
with shake flask studies carried out using the same construct
(Browning et al., 2017), but we considered it important to assess the
export of a “linker‐less” construct lacking any linker residues,
because industrial processes are unlikely to incorporate such linkers.
We therefore removed the four residues and also removed the hGH
initiation methione so that the processed form would correspond to
authentic hGH. We carried out fed‐batch fermentation studies on
this “clean” construct and the periplasmic fractions are analyzed in
Figure 8. The immunoblot and gel data show that hGH production is
induced and that high levels of hGH are exported to the periplasm
over the 38 hr induction period. As with the original construct,
periplasmic hGH accumulates to the extent that it is a highly
F IGURE 6 Exported periplasmic hGH is homogeneous and cleaved at the correct site. Periplasmic hGH was purified by affinity
chromatography (see Figure S1) and subjected to mass spectrometry analysis as detailed in Materials and Methods. Commercial hGH was
analyzed in an identical manner. The mass spectra for commercial hGH is shown in panel (a) and for periplasmic hGH in (b). (c) Amino acid
sequence of TorA–hGH–H6. The C‐terminal half of the TorA signal peptide is shown, along with the first five amino acids of the mature TMAO
protein and the initial methionine for the hGH protein. The signal peptidase cleavage site between ATA and AQA is denoted by ♦. The sequence
for the commercial hGH is underlined, and this is followed by the 6‐histidine tag. hGH, human growth hormone
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abundant periplasmic protein. The data thus show that removal of
the four‐residue linker does not block export of hGH, and that export
proceeds in the absence of the hGH initiation methionine.
Figure 9 shows a direct comparison of the export of the two hGH
forms, in which fermentation samples were fractionated into
cytoplasm, membrane, and periplasm extracts, which were then
blotted for the presence of hGH. The data show that in each case, the
majority of hGH is present in the periplasm, confirming that both
constructs are efficiently exported. However, the hGH immunoblot
signal after export of the linker‐less construct is less intense than
that of the original construct containing the additional four residues
(Figure 9a). In addition, analysis of the stained gel in Figure 9b shows
that while the linker‐less periplasmic hGH is a major band, the
abundance is not as striking as that of the periplasmic accumulation
of hGH observed in Figures 2 and 3. We, therefore, believe that the
linker‐less hGH is exported with lowered efficiency, and quantifica-
tion of the blots suggests that, on average, its export is in the region
of 50% as efficient as that of the original TorA–hGH construct.
4 | DISCUSSION
The Tat system has been proposed to offer a viable alternative to the
Sec pathway for the export of high‐value proteins to the bacterial
periplasm, but its potential for the production of biotherapeutic
proteins has not been fully explored in previous studies. This is
primarily because the majority of those studies were carried out
using laboratory shake flask culture systems, whereas industrial
processes almost invariably use fed‐batch fermentation. Here, we
have used fed‐batch fermentation systems to test the robustness of
the TatExpress cells and the yields of hGH that are obtained after
export to the periplasm.
A major aim in this work was to test for any deleterious effects
due to the increased expression of the TatABC membrane proteins
in the TatExpress strain. While the TatABC proteins are expressed
to a much lower extent than TorA–hGH, the increased expression
of any membrane protein can potentially lead to cell stress and
lowered productivity in extended fed‐batch fermentation systems.
Here, we directly compared the growth characteristics of the
TatExpress strain with its parental W3110 strain and we observed
no significant differences. Clearly, TatExpress strains are viable
production hosts.
F IGURE 7 Periplasmic hGH is disulfide bonded after fed‐batch
fermentation. Samples of the periplasmic fraction from the 51 hr
time point shown in Figure 3 were run (in triplicate) on an SDS
polyacrylamide gel under standard reducing conditions (“reducing” or
in the absence of reducing agent (“oxidizing”). The samples were
immunoblotted using antibodies to the C‐terminal His tag on hGH.
hGH “ox” and “red”: Oxidized and reduced forms of hGH,
respectively. Mobilties of molecular mass markers (in kDa) are shown
on the left. hGH, human growth hormone; SDS, sodium dodecyl
sulfate
F IGURE 8 Export of “linker‐less” TorA–hGH (hGH(ls)) during fed‐
batch fermentation of TatExpress cells. TorA–hGH lacking a four‐
residue linker and the hGH initiation methionine was expressed in
TatExpress cells in a fed‐batch fermentation system and samples
were removed at the indicated times postinduction (PI). The samples
were fractionated to generate periplasm samples which were then
analyzed on Coomassie blue stained gels (a) and by immunoblotting
using antibodies to the His tag on hGH (b)
F IGURE 9 Comparison of export rates for hGH containing or
lacking four additional residues at the N‐terminus. TorA–hGH
constructs containing four additional residues (as in Figures 2 and 3)
or “linker‐less”, lacking any additional residues between the signal
peptide and mature protein (as in Figure 8; denoted hGH(ls)) were
expressed in TatExpress cells as in the above Figures. After an
induction period of 40 hr, cells were fractionated into cytoplasm,
membrane, and periplasm samples (C, M, and P) which were analyzed
by immunoblotting (a) and on Coomassie‐stained SDS gels
(b). * denote the mobilities of the mature hGH proteins. TorA–hGH,
TorA signal peptide linked to hGH
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In terms of target protein yield, we consistently observe that
the cells export TorA–hGH throughout an extended induction
period and it is notable that the exported hGH is by far the most
abundant periplasmic protein by the end of the induction period. In
control tests, mature‐size hGH is not exported at all and we can
conclude that TorA–hGH is exported by the TorA signal peptide as
reported in shake flask studies (Alanen et al., 2015). The yields of
protein are high: the bioassay indicates a yield of over 5 g/L active
purified protein while the ELISA gives a figure of 2.39 g/L. This is
one of the highest yields reported and clear evidence that this
platform has potential for industrial use. Nevertheless, further
study would serve to illustrate the potential in more detail, and it
is notable that, while a “clean” fusion of a Tat signal peptide and
hGH is efficiently exported, the presence of a short linker region
appears to enhance export. An optimal signal peptide‐passenger
protein junction may be an important factor for efficient Tat‐
dependent export, as previously suggested by Tullman‐Ercek et al.
(2007).
In summary, we have shown that a model biotherapeutic protein
can be exported by the Tat system in high amounts, and that it is
homogeneous, disulfide bonded and active. It will be of interest to
conduct further studies to assess the full capability of the Tat system,
and in particular to explore its potential for the export of more
complex proteins.
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